儿童静脉血栓栓塞症临床试验疗效与安全性结局定义的更新指南:国际血栓与止血学会儿科与新生儿血栓与止血科学标准化委员会通讯
国际血栓与止血学会儿科与新生儿血栓与止血科学标准化委员会组织工作组,基于近期儿童抗血栓试验所用定义、成人研究推荐定义及监管指南,更新儿童静脉血栓栓塞症临床试验的疗效与安全性结局定义。主要更新包括将VTE相关死亡从复合主要结局中移除、明确纳入所有深静脉解剖部位,并新增「患者重要出血、无需干预」严重程度类别。
要点
- 疗效结局更新:VTE相关死亡不再作为复合主要结局的一部分。
- 疗效结局更新:明确纳入所有深静脉解剖部位。
- 安全性结局新增「患者重要出血、无需干预」类别,月经出血符合标准时可归入任何出血类别。
核心结论
- 工作组希望更新后的结局定义使研究者聚焦临床相关和患者重要的结局,并为儿童抗血栓治疗提供标准化以促进持续高质量证据。
研究设计与样本
- 国际血栓与止血学会科学标准化委员会儿科与新生儿血栓与止血分会组织工作组制定本更新指南。
- 工作组汇总并综述了近期儿童抗血栓试验所用结局定义、成人研究推荐定义及监管指南,作为本更新指南的基础。
主要发现
- 自2011年以来儿童静脉血栓栓塞症临床试验的标准化安全性和有效性结局定义未更新。
- 近期许多试验改编了推荐定义,导致结局异质性并限制研究间比较。
关键数值与推荐
- 疗效结局主要更新包括将VTE相关死亡从复合主要结局中移除。
- 疗效结局主要更新包括明确纳入所有深静脉解剖部位。
- 安全性结局更新新增出血严重程度类别:患者重要出血、无需干预,涵盖患者寻求诊疗但管理无变化的出血。
- 月经出血在符合标准时可纳入任何出血类别。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Despite the growing number of pediatric antithrombotic clinical trials, standardized safety and efficacy outcome definitions for pediatric venous thromboembolism (VTE) clinical trials have not been updated since 2011. Many recent trials have adapted the recommended definitions, leading to heterogeneity in outcomes and limiting our ability to compare studies. The International Society on Thrombosis and Haemostasis Scientific and Standardization Subcommittee (SSC) on Pediatric and Neonatal Thrombosis and Hemostasis organized a Task Force to update the efficacy and safety outcome definitions for pediatric VTE clinical trials. The outcome definitions used in the recent pediatric antithrombotic trials, definitions recommended for adult studies, and regulatory guidelines were summarized and reviewed by the Task Force as the basis for this updated guidance. Major updates to the efficacy outcomes include the removal of VTE-related mortality as a part of a composite primary outcome and explicit inclusion of all deep venous anatomic sites. Safety outcomes were updated to include a new bleeding severity category: patient important bleeding, no intervention, which encompasses bleeding for which a patient seeks care but there is no change in management. Menstrual bleeding can now be included in any bleeding category when the criteria are met. We hope that these updated outcome definitions will allow the investigators to focus on clinically relevant and patient-important outcomes and provide standardization to facilitate continued high-quality evidence for the use of antithrombotic therapies in children.
引用
- Whitworth H, Amankwah EK, Betensky M, et al. Updated guidance for efficacy and safety outcomes for clinical trials in venous thromboembolism in children: communication from the ISTH SSC Subcommittee on Pediatric and Neonatal Thrombosis and Hemostasis. J Thromb Haemost. 2023. PMID: 36921919. doi:10.1016/j.jtha.2023.03.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。